Can SGLT2 inhibitors slow chronic kidney disease progression?

Who benefits most from SGLT2 inhibitors for CKD?

The strongest evidence shows that SGLT2 inhibitors slow CKD progression in a broad range of patients, including those with and without type 2 diabetes. A 2025 meta-analysis of seven randomized controlled trials (69,827 participants) found a 29% reduction in CKD progression risk (hazard ratio 0.71) and a 13% reduction in all-cause mortality (hazard ratio 0.87) [1]. The kidney benefit was actually numerically larger in non-diabetic patients (HR 0.64) compared to those with diabetes, though the difference wasn't statistically significant [1]. This means the drugs work regardless of diabetes status, which is a key point for many patients.

However, the benefit may not be equal for everyone. A 2025 review raises an important caveat: most major trials enrolled overweight or obese patients with advanced CKD, where sodium retention and glomerular hyperfiltration are key drivers of disease [9]. In lean individuals (BMI under 25) with non-diabetic CKD—such as those with Alport syndrome or immune-mediated glomerular diseases—the benefit may be minimal or absent [9]. This is because SGLT2 inhibitors work partly by reducing intraglomerular pressure through tubuloglomerular feedback, a mechanism that may be less relevant in these subgroups [7][9]. So while the drugs are a game-changer for many, they may not be a universal solution.

Albuminuria level also matters. A 2024 analysis estimated that among US adults with CKD, full adoption of SGLT2 inhibitors could prevent 377,000 CKD progression events over three years, but this projection is based on trials that enriched for high-risk patients (UACR >200 mg/g or eGFR 20-45) [5]. For patients with moderately increased albuminuria (UACR 30-200 mg/g) who don't meet current trial criteria, the potential benefit is less certain, though the same analysis suggests 219,000 CKD progression events could still be prevented if the drugs work similarly in this group [5].

How do SGLT2 inhibitors protect the kidneys, and what should you expect?

The kidney protection from SGLT2 inhibitors goes beyond blood sugar control. A key mechanism is tubuloglomerular feedback: by blocking glucose and sodium reabsorption in the proximal tubule, more sodium reaches the macula densa, which signals the afferent arteriole to constrict [7]. This reduces intraglomerular pressure, protecting the filtering units from damage. The drugs also improve tubular oxygenation, reduce inflammation and fibrosis, and lower blood pressure and uric acid levels [2][7].

When starting an SGLT2 inhibitor, you should expect a small, temporary dip in kidney function. A 2022 study of 49 CKD patients found a median eGFR drop from 58 to 53 mL/min/1.73m² after 4 months, which is expected and not a cause for alarm [3]. This initial dip is a hemodynamic effect, not kidney damage, and the long-term benefit is a slower rate of decline. The same study also showed improvements in blood pressure (systolic from 136 to 132 mmHg) and glycemic control (HbA1c from 7.2% to 6.1%) [3].

The benefits take time to accrue. A 2024 review notes that while the beneficial effects may not be immediately apparent, they are expected to grow over time, potentially altering the prognosis for many CKD patients [10]. This is why adherence is important—the drugs are a long-term therapy, not a quick fix.

Are SGLT2 inhibitors safe in CKD? What are the risks?

Overall, SGLT2 inhibitors have a favorable safety profile in CKD. A 2023 meta-analysis of 13 randomized trials found no increased risk of serious adverse events or urinary tract infections [8]. However, they do increase the risk of reproductive tract infections (genital mycotic infections), which is a known class effect [8]. In the 2022 study of 49 patients, only two were excluded due to intolerance, and one due to non-adherence, suggesting good tolerability [3].

There are important precautions. The drugs should be used with caution in patients with very low GFR (CKD stage 4 and beyond), as the initial dip in eGFR can be more pronounced [7]. It's also prudent to stop the drug temporarily during acute illness, hypovolemia, or hypotension [7]. A 2024 post-hoc analysis of the EMPA-KIDNEY trial is investigating whether frailty affects the risk-benefit profile, but results are not yet available [6].

Importantly, SGLT2 inhibitors do not appear to worsen diabetic retinopathy. A 2023 retrospective study of over 6,000 patients found no increased risk of vision-threatening diabetic retinopathy, diabetic macular edema, or proliferative diabetic retinopathy compared to standard care [4]. This addresses a common concern among patients with diabetes.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2022 to 2025, 6 from 2024 or later, 6 in Q1 journals, collectively cited 276 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 56 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions